Pharmaceutical salts of an orexin receptor antagonist
The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
1. Crystalline suvorexant hydrochloride which is characterized by a solid-state carbon-13 cross-polarization magic-angle spinning nuclear magnetic resonance spectrum having peaks corresponding to 17.4, 19.1, 45.9, 126.9, 128.9 and 130.0 p.p.m.
2. The crystalline suvorexant hydrochloride of claim 1 which is further characterized by an x-ray powder diffraction pattern, collected using copper K-alpha radiation, exhibiting characteristic diffraction peaks corresponding to d-spacings of 3.3, 3.5, 4.4, 5.6, 6.0 and 42.5 angstroms.
3. Crystalline suvorexant methanesulfonate characterized by an x-ray powder diffraction pattern, collected using copper K-alpha radiation, having at least five characteristic peaks selected from the group consisting of 12.6, 16.0, 16.4, 18.0, 19.3, 19.8, 20.2, 21.7, 24.5 and 25.5° 2Theta.
4. The crystalline suvorexant methanesulfonate of claim 3 which is further characterized by an x-ray powder diffraction pattern exhibiting characteristic diffraction peaks corresponding to d-spacings of 4.1, 4.5, 4.6, 4.9, 5.4 and 5.5 angstroms.
5. Crystalline suvorexant dodecyl sulfate characterized by an x-ray powder diffraction pattern, collected using copper K-alpha radiation, having at least five characteristic peaks selected from the group consisting of 4.3, 12.9, 15.8, 18.0, 19.5, 21.4, 21.5 and 23.2° 2Theta.
6. The crystalline suvorexant dodecyl sulfate of claim 5 which is further characterized by an x-ray powder diffraction pattern having d-spacings of 3.8, 4.1, 4.2, 5.6, 6.9 and 20.3 angstroms.
7. Crystalline suvorexant p-toluenesulfonate characterized by an x-ray powder diffraction pattern, collected using copper K-alpha radiation, having at least five characteristic peaks selected from the group consisting of 5.5, 8.3, 11.1, 13.9, 16.0, 16.7, 19.6 and 26.1° 2Theta.
8. Crystalline suvorexant p-toluenesulfonate of claim 7 which is further characterized by an x-ray powder diffraction pattern exhibiting characteristic diffraction peaks corresponding to d-spacings of 4.5, 5.5, 6.4, 8.0, 10.7 and 16.2 angstroms.
9. Crystalline suvorexant p-toluenesulfonate of claim 7 which is further characterized by DSC themal analysis that shows a melting point endotherm at 157.9° C.
10. A pharmaceutical composition comprising suvorexant hydrochloride of claim 1 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising suvorexant methanesulfonate of claim 3 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising suvorexant dodecyl sulfate of claim 5 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising suvorexant p-toluenesulfonate of claim 7 and a pharmaceutically acceptable carrier.
14. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of suvorexant hydrochloride of claim 1 .
15. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of suvorexant methanesulfonate of claim 3 .
16. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of suvorexant dodecyl sulfate of claim 5 .
17. A method for treating insomnia in a human patient in need thereof which comprises administering to the patient a therapeutically effective amount of suvorexant p-toluenesulfonate of claim 7 .